Skip to main content
    T

    Telomir Pharmaceuticals, Inc. Common Stock (TELO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.48
    -0.01 (-1.96%)

    Market Cap: $36.15M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Telomir Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$10.41M, operating cash flow was -$3.69M and free cash flow was -$3.69M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$705.23K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $10.54M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$0N/AN/AN/AN/A
    Sep 2024$0N/AN/AN/AN/A
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Sep 2021 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Cost of revenueN/AN/A$3.94MN/AN/A
    Gross profitN/AN/A-$3.94MN/AN/A
    Research and development$2.44M$2.24M$1.57M$833.21K$126.49K
    Operating income-$10.54M-$12.24M-$3.94M-$854.15K-$138.13K
    Net income-$10.41M-$16.53M-$13.07M-$854.15K-$138.13K
    EBITDA-$10.41M-$7.86MN/A-$854.15K-$138.13K
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$18.79M$0$0$0$0
    Gross profitN/AN/AN/AN/AN/AN/AN/A$9.40M-$6.01M-$1.47M-$1.92MN/A
    Operating income-$745.20K-$1.76M-$1.04M-$2.13M-$1.15M-$5.07M-$2.19M-$2.91M-$6.01M-$1.47M-$1.92M-$1.08M
    Net income-$705.23K-$1.72M-$990.95K-$2.06M-$1.10M-$5.07M-$2.18M-$2.90M-$5.99M-$1.45M-$6.25M-$9.33M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of $473.75K by $6.81M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Total assets$7.34M$1.32M$4.77M$48.73K$55.00K
    Current assets$7.34M$1.32M$435.23K$1.42K$0
    Cash and equivalents$7.29M$1.27M$1.23K$1.42K$0
    Total liabilities$1.43M$680.97K$1.34M$986.01K$138.13K
    Short-term debt$473.75K$93.43K$101.00K$581.79K$119.40K
    Shareholder equity$5.91M$643.04K$3.44M-$937.28K-$83.13K
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$4.64M$5.37M$5.79M$7.34M$7.40M$829.61K$491.19K$1.32M$1.04M$2.10M$3.50M$4.77M
    Total liabilities$236.75K$332.42K$827.31K$1.43M$422.81K$348.39K$652.29K$680.97K$599.91K$534.15K$486.55K$1.34M
    Cash and equivalents$4.52M$5.17M$5.56M$7.29M$7.33M$754.32K$403.00K$1.27M$834.64K$1.88M$3.27M$1.23K
    Shareholder equity$4.40M$5.03M$4.96M$5.91M$6.98M$481.22K-$161.11K$643.04K$442.07K$1.57M$3.02M$3.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
    Operating cash flow-$3.69M-$5.07M-$3.86M-$468.66K-$119.40K
    Capital expenditures$0$0$4$0$4
    Free cash flow-$3.69M-$5.07M-$3.86M-$468.66K-$119.40K
    Financing cash flow$9.71M$6.34M$3.86M$470.08K$119.40K
    Fiscal years ended Sep 2021 to Sep 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$586.44K-$1.01M-$1.77M-$1.20M-$927.26K-$696.45K-$863.13K-$605.81K-$1.00M-$1.52M-$1.94M-$1.09M
    Capital expenditures$0$0$0$3$5$4$0$2$0$0$5$5
    Free cash flow-$586.44K-$1.01M-$1.77M-$1.20M-$927.27K-$696.45K-$863.13K-$605.81K-$1.00M-$1.52M-$1.94M-$1.09M
    Last 12 quarters

    Frequently Asked Questions About TELO

    What is Telomir Pharmaceuticals, Inc. Common Stock's annual revenue?

    Telomir Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025.

    Is Telomir Pharmaceuticals, Inc. Common Stock profitable?

    No. Telomir Pharmaceuticals, Inc. Common Stock reported net income of -$10.41M for the fiscal year ended Sep 30, 2025.

    How much free cash flow does TELO generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$3.69M minus capital expenditures of $0 produced free cash flow of -$3.69M.

    How much debt does Telomir Pharmaceuticals, Inc. Common Stock have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $473.75K and cash and equivalents of $7.29M.